Probable everolimus-associated severe colitis with hematochezia in a patient with metastatic hormone receptor–positive, HER2-negative breast cancer: a case report
Ahmad Fatayer, Salem K. Qupp, Joyce Morcos, ZainEdeen Zyadah, Alaa Alresheq, Jahed Bushnaq, Marwan Qubaja, Ola Abu Laban · 2026
Read Probable everolimus-associated severe colitis with hematochezia in a patient with metastatic hormone receptor–positive, HER2-negative breast cancer: a case report by Ahmad Fatayer, Salem K. Qupp, Joyce Morcos, ZainEdeen Zyadah, Alaa Alresheq, Jahed Bushnaq, Marwan Qubaja, Ola Abu Laban (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13619945.txt.
Description
Ahmad Fatayer and co-authors report severe colon inflammation with bleeding likely caused by a breast cancer drug. Their 2026 case covers a sixty-year-old woman with spread hormone-positive breast cancer on everolimus plus hormone therapy. Diarrhea is a known side effect; bleeding colitis is rare and poorly mapped.
Six months into therapy she arrives with two days of severe belly pain and bloody stools. Scans show thick, swollen colon walls on the right side. Scope and biopsy find chronic active inflammation with surface erosion, no infection, no bowel disease, and no cancer. Virus tests and stool checks come back negative. The drug is stopped for good. The authors present the case to alert clinicians that a common cancer pill can, rarely, wound the colon badly.
Catalog record
| CREATOR | Ahmad Fatayer, Salem K. Qupp, Joyce Morcos, ZainEdeen Zyadah, Alaa Alresheq, Jahed Bushnaq, Marwan Qubaja, Ola Abu Laban |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 40 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |